AN2 Therapeutics (ANTX) news
Recent news
An2 Therapeutics reports positive enabling data
AN2 Therapeutics, Inc. (Nasdaq: ANTX) has reported positive enabling data for its boron chemistry platform, supporting the advancement of multiple programs into clinical development. The company highlighted progress across its pipeline, including the oral epetraborole program for polycythemia vera,…
AInvest Wire · Jun 4, 2026AN2 Therapeutics shares dropped 73% to $5.35 after the company announced it will voluntarily pause enrollment in the Phase 3 part of the Phase 2/3 pivotal clinical trial
AN2 Therapeutics shares dropped 73% to $5.35 after the company announced it will voluntarily pause enrollment in the Phase 3 part of the Phase 2/3 pivotal clinical trial AN2 Therapeutics, a clinical-stage biotechnology company, recently announced that it will voluntarily pause enrollment in the…
AInvest Wire · Feb 12, 2024AN2 Therapeutics: grant for therapies for tuberculosis, malaria
AInvest Wire · Sep 26, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.